Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma
- PMID: 21262951
- PMCID: PMC3164998
- DOI: 10.1373/clinchem.2010.153320
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma
Abstract
Background: Pheochromocytomas are rare catecholamine-producing tumors derived in more than 30% of cases from mutations in 9 tumor-susceptibility genes identified to date, including von Hippel-Lindau tumor suppressor (VHL); succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB); and succinate dehydrogenase complex, subunit D, integral membrane protein (SDHD). Testing of multiple genes is often undertaken at considerable expense before a mutation is detected. This study assessed whether measurements of plasma metanephrine, normetanephrine, and methoxytyramine, the O-methylated metabolites of catecholamines, might help to distinguish different hereditary forms of the tumor.
Methods: Plasma concentrations of O-methylated metabolites were measured by liquid chromatography with electrochemical detection in 173 patients with pheochromocytoma, including 38 with multiple endocrine neoplasia type 2 (MEN 2), 10 with neurofibromatosis type 1 (NF1), 66 with von Hippel-Lindau (VHL) syndrome, and 59 with mutations of SDHB or SDHD.
Results: In contrast to patients with VHL, SDHB, and SDHD mutations, all patients with MEN 2 and NF1 presented with tumors characterized by increased plasma concentrations of metanephrine (indicating epinephrine production). VHL patients usually showed solitary increases in normetanephrine (indicating norepinephrine production), whereas additional or solitary increases in methoxytyramine (indicating dopamine production) characterized 70% of patients with SDHB and SDHD mutations. Patients with NF1 and MEN 2 could be discriminated from those with VHL, SDHB, and SDHD gene mutations in 99% of cases by the combination of normetanephrine and metanephrine. Measurements of plasma methoxytyramine discriminated patients with SDHB and SDHD mutations from those with VHL mutations in an additional 78% of cases.
Conclusions: The distinct patterns of plasma catecholamine O-methylated metabolites in patients with hereditary pheochromocytoma provide an easily used tool to guide cost-effective genotyping of underlying disease-causing mutations.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3164998/bin/nihms318691f1.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3164998/bin/nihms318691f2.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3164998/bin/nihms318691f3.gif)
Comment in
-
Gene targeting through o-methylated catecholamine metabolite patterns.Clin Chem. 2011 Mar;57(3):361-2. doi: 10.1373/clinchem.2010.159178. Epub 2011 Jan 18. Clin Chem. 2011. PMID: 21245368 No abstract available.
Similar articles
-
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.N Engl J Med. 1999 Jun 17;340(24):1872-9. doi: 10.1056/NEJM199906173402404. N Engl J Med. 1999. PMID: 10369850
-
Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.Clin Chem Lab Med. 2020 Oct 1;59(2):353-363. doi: 10.1515/cclm-2020-0904. Clin Chem Lab Med. 2020. PMID: 33001846
-
Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy.Clin Chim Acta. 2019 Jul;494:100-105. doi: 10.1016/j.cca.2019.03.1620. Epub 2019 Mar 20. Clin Chim Acta. 2019. PMID: 30904545
-
Laboratory evaluation of pheochromocytoma and paraganglioma.Clin Chem. 2014 Dec;60(12):1486-99. doi: 10.1373/clinchem.2014.224832. Epub 2014 Oct 20. Clin Chem. 2014. PMID: 25332315 Review.
-
Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.Fam Cancer. 2005;4(1):13-6. doi: 10.1007/s10689-004-6128-y. Fam Cancer. 2005. PMID: 15883705 Review.
Cited by
-
Case report: Rare case of a preoperatively diagnosed spermatic cord paraganglioma and literature review.Front Oncol. 2024 Apr 11;14:1373727. doi: 10.3389/fonc.2024.1373727. eCollection 2024. Front Oncol. 2024. PMID: 38680861 Free PMC article.
-
Diagnosis, Genetics, and Management of 24 Patients With Cardiac Paragangliomas: Experience From a Single Center.J Endocr Soc. 2023 Jul 10;7(9):bvad093. doi: 10.1210/jendso/bvad093. eCollection 2023 Aug 2. J Endocr Soc. 2023. PMID: 37873498 Free PMC article.
-
Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas.Curr Cardiol Rep. 2023 Nov;25(11):1451-1460. doi: 10.1007/s11886-023-01974-8. Epub 2023 Oct 17. Curr Cardiol Rep. 2023. PMID: 37847359 Review.
-
Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes.Endocr Oncol. 2022 Jun 28;2(1):R65-R77. doi: 10.1530/EO-22-0044. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435466 Free PMC article. Review.
-
Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.Cancer Med. 2023 Jul;12(13):13942-13957. doi: 10.1002/cam4.6010. Epub 2023 May 5. Cancer Med. 2023. PMID: 37145019 Free PMC article. Review.
References
-
- Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75. - PubMed
-
- Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95:1196–204. - PubMed
-
- Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812–8. - PubMed
-
- Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94:1541–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous